Medical News

RSS

ANTIPAF trial reveals ARBs do not reduce number of AF episodes in paroxysmal AF patients

Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting about 7 million people in Europe. It is a progressive chronic disease in which episodes become more frequent and long-lasting over time. Conventional anti-arrhythmic therapy aims at halting progression and reducing symptoms, but the use of most anti-arrhythmic drugs is compromised by severe side effects, such as pro-arrhythmia or extra-cardiac organ toxicity.

31 Aug 2010

Data monitoring committee recommends early termination following impressive results of AVERROES study

The data monitoring committee of the AVERROES study, seeing overwhelming evidence of the success of apixaban in the prevention of stroke in patients with atrial fibrillation who are unsuitable for the conventional treatment of warfarin, has recommended early termination of this study. The decision came after repeated review and careful consideration of all efficacy and safety data.

31 Aug 2010

TPP and University of Edinburgh collaborate on development of novel pre-clinical intellectual property

TPP Global Development Ltd (TPP) announced an agreement with the University of Edinburgh to collaborate on the development of novel pre-clinical intellectual property originated within the University.

31 Aug 2010

$Unfractionated heparin standard dose may be optimal treatment strategy in PCI patients on fondaparinux$

Unfractionated heparin standard dose may be optimal treatment strategy in PCI patients on fondaparinux

Results from the FUTURA/OASIS 8 study presented today at the ESC Congress provide initial evidence that a low dose of unfractionated heparin does not reduce the incidence of bleeding or vascular complications in PCI patients treated with the anticoagulant fondaparinux. Findings showed that the rates of peri-PCI major bleeding were 1.4% in those given low dose heparin and 1.2% the standard dose.

31 Aug 2010

A-Life Medical ranked #2513 on 2010 Inc. 500|5000 list of fastest-growing, private companies

A-Life Medical, Inc., the pioneer and leading provider of computer-assisted coding (CAC) products and services to the healthcare industry, announced today it has been included in the 2010 Inc. 500|5000 list of the fastest-growing, private companies in America. A-Life Medical ranked 2513 in its inaugural appearance on the list.

31 Aug 2010

Greater clarity on legal implications of testing incapacitated patients for blood-borne viruses needed

Anaesthetists are calling for greater clarity on the legal implications of testing incapacitated patients for blood-borne viruses, after a survey found that this is often done following staff needlestick injuries, in possible breach of UK legislation.

31 Aug 2010

Prolonged exercise shows no evidence of cardiac fatigue: Research

In a research project aimed at understanding the effect of prolonged exercise on the heart, the Karolinska Institutet and the Swedish School of Sport and Health Sciences studied a group of competitors taking part in the Adventure Racing World Championship. The results show no evidence of cardiac fatigue despite the fact that this is a continuous endurance event lasting between five and seven days.

31 Aug 2010

Death toll expected to rise as flooding subsides in some parts of Pakistan

Pakistani government officials say the death toll from the country's flooding stands at more than 1,600 and it could rise significantly as flood waters recede and more bodies are identified, CNN reports (8/28). "There is no official estimate of the number of missing because mass displacements have made accounting for them almost impossible," according to Reuters (Haider, 8/29).

31 Aug 2010

Study finds black females exhibit greater magnitude of LVH than their white counterparts

A study conducted in the UK has established the extent of cardiac adaptation amongst female athletes competing in a number of sports.

31 Aug 2010

UBC researchers lead development of new 'toolbox of MiniPromoters' for gene research and therapy

University of British Columbia researchers have led the development of a new "toolbox of MiniPromoters" for research and future therapies on brain, spinal cord and eye function.

31 Aug 2010

Study evaluates response to psychotherapeutical interventions in anorexia nervosa

This study demonstrates that the distinction between threshold and subthreshold anorexia nervosa does not seem to be of clinical relevance in terms of response to cognitive-behavioral therapy (CBT). Shape concern rather than demographic or general psychopathological features represents the best predictor of outcome for CBT.

31 Aug 2010

Running continuously over 50 or 100 miles may not be good for the heart: Study

In 2009, a study was conducted in UK by Liverpool John Moores University and the Countess of Chester Hospital to assess the effects of running in ultra-endurance races. Typically aimed at super-fit and experienced athletes, these races are held over distances exceeding 50 miles (80 kilometres). The conclusions suggest that some damage is likely to occur to the heart muscle of competitors, while 12 percent of the study group showed signs of significant cardiac damage.

31 Aug 2010

Advanced Life Sciences scientific publication demonstrates triterpenoids' potential as anticancer agents

Advanced Life Sciences Holdings, Inc.,a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced the publication of a research paper in the journal Bioorganic and Medicinal Chemistry Letters that reports data using the Company's core triterpenoid platform technology in the discovery and development of new cancer therapeutic agents.

31 Aug 2010

Telmisartan and amlodipine combination therapy helps achieve high BP control/response rates

Data show that treatment with a single-pill combination of telmisartan, an angiotensin receptor blocker, (ARB) and amlodipine, a calcium channel blocker (CCB) results in significant reductions in blood pressure (BP) in patients with severe hypertension.

31 Aug 2010

Bionovo receives positive guidance for Menerba drug candidate

Bionovo, Inc. announced today that it has received positive guidance from the U.S. Food and Drug Administration (FDA) regarding the Company's Chemistry, Manufacturing and Controls (CMC) plan for its lead drug candidate Menerba.

31 Aug 2010

ESC/EACTS releases new Myocardial Revascularisation guidelines

Multivessel and left main disease have been long considered as mainstay indications for coronary artery bypass grafting surgery (CABG). This recommendation, however, has been strongly challenged on several occasions. The release of new Myocardial Revascularisation guidelines by ESC and the European Association of Cardio-Thoracic Surgeons (EACTS) at the ESC Congress on Sunday 29 August is likely to shed new light on what has become a controversial topic.

31 Aug 2010

SCOLR Pharma signs sales support agreement with Emerson Group

SCOLR Pharma, Inc. today announced that it has signed an agreement with The Emerson Group to provide sales support for the Company's new line of extended-release nutritional and over-the-counter drug products.

31 Aug 2010

Phase 3 EINSTEIN-DVT clinical trial data can transform deep vein thrombosis treatment

Johnson & Johnson Pharmaceutical Research & Development, announced today that the investigational, oral anticoagulant rivaroxaban successfully demonstrated non-inferiority compared to the standard of care for the prevention of recurrent venous thromboembolism (VTE) in patients with acute symptomatic deep vein thrombosis (DVT), with a comparable safety profile.

31 Aug 2010

Marathon running does not cause sustained heart damage

A study of 167 amateur runners at the 2006 and 2007 Berlin marathons is lowering concerns that this type of activity leads to sustained heart damage, particularly among older competitors. Marathons are becoming an increasingly popular challenge for amateur runners wanting to test their endurance over the classic 26-mile distance. The medical community, however, has long been concerned about how marathons impact the heart - and it has not yet been shown if the effects vary among different age groups or genders.

31 Aug 2010

Bioheart's MyoCell adult stem cell therapy shows effective for heart failure patients: Study

Bioheart, Inc., The mission of the Cell Therapy Foundation is to improve public health through the support of effective adult stem cell research and education. The Foundation aims to promote basic and applied knowledge, processes and cell therapies.

31 Aug 2010

Medical News

ANTIPAF trial reveals ARBs do not reduce number of AF episodes in paroxysmal AF patients

Data monitoring committee recommends early termination following impressive results of AVERROES study

TPP and University of Edinburgh collaborate on development of novel pre-clinical intellectual property

Unfractionated heparin standard dose may be optimal treatment strategy in PCI patients on fondaparinux

A-Life Medical ranked #2513 on 2010 Inc. 500|5000 list of fastest-growing, private companies

Greater clarity on legal implications of testing incapacitated patients for blood-borne viruses needed

Prolonged exercise shows no evidence of cardiac fatigue: Research

Death toll expected to rise as flooding subsides in some parts of Pakistan

Study finds black females exhibit greater magnitude of LVH than their white counterparts

UBC researchers lead development of new 'toolbox of MiniPromoters' for gene research and therapy

Study evaluates response to psychotherapeutical interventions in anorexia nervosa

Running continuously over 50 or 100 miles may not be good for the heart: Study

Advanced Life Sciences scientific publication demonstrates triterpenoids' potential as anticancer agents

Telmisartan and amlodipine combination therapy helps achieve high BP control/response rates

Bionovo receives positive guidance for Menerba drug candidate

ESC/EACTS releases new Myocardial Revascularisation guidelines

SCOLR Pharma signs sales support agreement with Emerson Group

Phase 3 EINSTEIN-DVT clinical trial data can transform deep vein thrombosis treatment

Marathon running does not cause sustained heart damage

Bioheart's MyoCell adult stem cell therapy shows effective for heart failure patients: Study

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Latest News